Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALCAFTADINE vs ACTRON
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective histamine H1 receptor antagonist; inhibits histamine release from mast cells and reduces ocular itch associated with allergic conjunctivitis.
Acetaminophen (paracetamol) is a non-opioid analgesic and antipyretic. Its mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, reducing prostaglandin synthesis. It also modulates the endocannabinoid system and serotonergic pathways.
FDA: Prevention of itching associated with allergic conjunctivitis,Off-label: No established off-label uses
Mild to moderate pain,Fever
1 drop of 0.25% ophthalmic solution in each affected eye twice daily.
Oral: 400 mg every 4-6 hours as needed for pain; maximum 1200 mg/day.
Terminal elimination half-life is approximately 2 hours (range 1.5–3 h) after topical ocular administration, appropriate for twice-daily dosing.
Terminal elimination half-life 2-4 hours; prolonged to 6-12 hours in elderly or renal impairment (Cr Cl <30 m L/min).
Not extensively metabolized; primarily excreted unchanged in urine. Cytochrome P450 metabolism is minimal.
Primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9), sulfation (SULT1A1, SULT1A3), and oxidation (CYP2E1, CYP3A4) to form the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI), which is detoxified by glutathione.
Primarily renal (approximately 50% unchanged), with the remainder as metabolites; negligible biliary/fecal elimination.
Renal: 90% as unchanged drug; biliary/fecal: 10% as metabolites.
Approximately 40% bound to plasma proteins.
>99% bound to albumin.
Vd is approximately 1.4 L/kg, indicating distribution beyond plasma into extravascular tissues.
0.1-0.2 L/kg; indicates limited extravascular distribution.
Systemic bioavailability after topical ocular administration is low (estimated < 0.5%) due to dilution, local metabolism, and limited corneal penetration.
Oral: 70-90% (first-pass metabolism minimal); IV: 100%.
No dose adjustment required for any degree of renal impairment.
GFR <30 m L/min: Avoid use. GFR 30-50 m L/min: Reduce dose to 50% of normal, maximum 600 mg/day.
No dose adjustment required for any degree of hepatic impairment.
Child-Pugh Class B: Reduce dose by 50%; maximum 600 mg/day. Child-Pugh Class C: Contraindicated.
Children 2 years and older: same as adult dose. Safety and efficacy in children under 2 years not established.
Children ≥12 years: 400 mg orally every 6-8 hours as needed; maximum 1200 mg/day. Children <12 years: Not recommended.
No specific dose adjustment needed; use same dose as for younger adults.
Initiate at 200 mg every 6-8 hours; maximum 600 mg/day due to increased risk of gastrointestinal bleeding and renal impairment.
None
Acetaminophen has been associated with cases of acute liver failure, sometimes resulting in liver transplant and death. Most cases involve use of acetaminophen at doses exceeding 4000 mg per day, often involving more than one acetaminophen-containing product.
Do not inject; for topical ophthalmic use only,Avoid wearing contact lenses if eyes are red,May cause temporary blurred vision after instillation,Use with caution in patients with known hypersensitivity
Hepatotoxicity: risk increased with chronic alcohol use, liver disease, or use of other acetaminophen-containing products. Avoid exceeding 4000 mg/day. Severe skin reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis. Hypersensitivity reactions: anaphylaxis.
Hypersensitivity to alcaftadine or any component of the formulation
Severe hepatic impairment or active liver disease. Known hypersensitivity to acetaminophen or any component of the formulation.
No specific food interactions reported. As an ophthalmic preparation, systemic absorption is minimal and unlikely to be affected by food.
Avoid alcohol; may increase risk of GI bleeding. No specific food restrictions, but taking with food can reduce gastrointestinal irritation. Maintain adequate hydration to prevent renal impairment.
Alcaftadine is classified as Pregnancy Category B. Animal studies have not demonstrated teratogenic effects at doses up to 2400 times the human ocular dose. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, alcaftadine should be used during pregnancy only if clearly needed.
First trimester: Based on animal studies and limited human data, possible increased risk of cardiovascular and neural tube defects. Second/third trimester: Risk of premature closure of ductus arteriosus and oligohydramnios with prolonged use. Avoid after 30 weeks gestation.
It is not known whether alcaftadine is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when alcaftadine is administered to a nursing woman. The M/P ratio has not been established.
Excreted in breast milk; M/P ratio 0.15. Low oral bioavailability to infant; considered compatible with breastfeeding. Monitor infant for sedation or feeding problems.
No pharmacokinetic studies have been performed in pregnant women. Based on the available animal data and the low systemic exposure after ocular administration, no dosing adjustment is recommended during pregnancy.
Dose adjustment not typically required; however, due to increased renal clearance and volume of distribution in pregnancy, higher doses may be needed to achieve therapeutic effect. Use lowest effective dose for shortest duration.
ALCAFTADINE is a topical ophthalmic antihistamine and mast cell stabilizer used for allergic conjunctivitis. Administer one drop twice daily in each affected eye. Onset of action is within minutes. Contraindicated in patients with hypersensitivity to any component. Use with caution in contact lens wearers; remove lenses before instillation and wait 10 minutes before reinserting. Do not touch dropper tip to any surface to avoid contamination.
ACTRON (ketorolac tromethamine) is a nonsteroidal anti-inflammatory drug (NSAID) for short-term management of moderate to severe acute pain, typically not exceeding 5 days due to risk of GI bleeding, renal impairment, and cardiovascular events. Avoid in patients with active peptic ulcer disease, bleeding diathesis, or advanced renal disease. Monitor renal function and signs of bleeding. Use lowest effective dose for shortest duration. May cause bronchospasm in aspirin-sensitive asthma.
Do not wear contact lenses if your eyes are red; after the redness subsides, wait at least 10 minutes after instilling the drop before reinserting lenses.,Do not touch the dropper tip to your eye or any surface to avoid contamination.,Wait at least 5 minutes between using this drug and other eye drops.,If you miss a dose, use it as soon as you remember; if it is almost time for the next dose, skip the missed dose and resume your regular schedule.,Do not use more than prescribed; overuse may cause eye irritation.,Tell your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Wash hands before and after use.
Take with food or milk to reduce stomach upset.,Do not take for more than 5 days as prescribed; longer use increases risk of serious side effects.,Avoid alcohol while taking this medication to lower risk of stomach bleeding.,Report any signs of bleeding (e.g., black stools, vomiting blood), unusual bruising, or decreased urination.,Do not take with other NSAIDs (e.g., ibuprofen, naproxen) or aspirin without consulting your doctor.,Inform your doctor about all medications, especially blood thinners (e.g., warfarin) and diuretics.,If you have asthma, be aware of potential bronchospasm; seek immediate help if you have breathing trouble.,Not recommended during pregnancy, especially in the third trimester.
"Dextroamphetamine, a central nervous system stimulant, may reduce the sedative effects of Alcaftadine, an antihistamine used for allergic conjunctivitis, by opposing its central histamine H1 receptor blockade. This pharmacodynamic antagonism can lead to diminished sedation and potentially decreased therapeutic efficacy of Alcaftadine for its intended ocular antiallergic effects. Patients may experience reduced symptom relief and increased ocular discomfort."
"Hydroxyamphetamine may decrease the sedative activities of Alcaftadine."
"Phentermine may decrease the sedative activities of Alcaftadine."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALCAFTADINE vs ACTRON, answered by our medical review team.
ALCAFTADINE is a Ophthalmic Antihistamine that works by Selective histamine H1 receptor antagonist; inhibits histamine release from mast cells and reduces ocular itch associated with allergic conjunctivitis.. ACTRON is a NSAID that works by Acetaminophen (paracetamol) is a non-opioid analgesic and antipyretic. Its mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, reducing prostaglandin synthesis. It also modulates the endocannabinoid system and serotonergic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALCAFTADINE and ACTRON depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALCAFTADINE is: 1 drop of 0.25% ophthalmic solution in each affected eye twice daily.. The standard adult dose of ACTRON is: Oral: 400 mg every 4-6 hours as needed for pain; maximum 1200 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALCAFTADINE and ACTRON in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALCAFTADINE is classified as Category C. Alcaftadine is classified as Pregnancy Category B. Animal studies have not demonstrated teratogenic effects at doses up to 2400 times the human ocular dose. There are no adequate a. ACTRON is classified as Category C. First trimester: Based on animal studies and limited human data, possible increased risk of cardiovascular and neural tube defects. Second/third trimester: Risk of premature closur. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.